JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Logu, A.
Right arrow Articles by Paolo Sanna, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Logu, A.
Right arrow Articles by Paolo Sanna, P.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 1998, p. 3198-3204, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Characterization of a Type-Common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential

Alessandro De Logu,1,2 R. Anthony Williamson,3 Roman Rozenshteyn,1 Fernando Ramiro-Ibañez,1 Cindy D. Simpson,1 Dennis R. Burton,3,4 and Pietro Paolo Sanna1,*

Departments of Neuropharmacology,1 Immunology,3 and Molecular Biology,4 The Scripps Research Institute, La Jolla, California, and Sezione di Microbiologia e Virologia, Dipartimento di Scienze Chirurgiche e Trapianti d'Organo Università di Cagliari, Cagliari, Italy2

Received 3 June 1998/Returned for modification 13 August 1998/Accepted 20 August 1998

We report the characterization of a type-common human recombinant monoclonal antibody previously isolated by antigen selection from a phage-displayed combinatorial antibody library established from a herpes simplex virus (HSV)-seropositive individual. Competition with well-characterized murine monoclonal antibodies and immunodetection of gD truncations revealed that this antibody recognizes the group Ib antigenic site of glycoprotein D, a highly conserved and protective type-common determinant. To our knowledge, this is the first human group Ib monoclonal antibody ever described. The antibody also displayed first-order neutralization kinetics and a high neutralization rate constant, was capable of completely inhibiting syncytium formation by a fusogenic strain of HSV type 1, and efficiently neutralized low-passage clinical isolates of both HSV serotypes. Taken together with our earlier observations of the in vivo antiviral activities of this human recombinant antibody in animal models of HSV infection, the present results support the high therapeutic potential of this antibody.

* Corresponding author. Mailing address: Department of Neuropharmacology, The Scripps Research Institute, CVN 12, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (619) 784-7180. Fax: (619) 784-7393. E-mail: psanna{at}Sage.scripps.edu.

Journal of Clinical Microbiology, November 1998, p. 3198-3204, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.